glp-1 cv outcome trials Cardiovascular outcomes in major with receptor agonists Cardiovascular and mortality outcomes with

While studies and assessments of GLP-1 AOMs, such as the cost-effectiveness study by the Institute for Clinical and Economic Review (ICER), 24 emphasize the potential for improved outcomes in obesity-related chronic diseases (e.g., heart disease, diabetes, osteoarthritis) and the potential related savings, the cost of AOMs must be paid up front, often exceeding the political or financial capacity of state legislatures to fund the program adequately

lean mass) and impacts on cardiometabolic health, NAFLD, and physical function

Cultural contexts that shape how care is delivered and received

The goal is to move from a V to an L development

National Institute on Drug Abuse

They help you feel full longer, reduce cravings, and support significant weight loss